The city of Dallas, Texas, currently has 13 active clinical trials seeking participants for COVID19 research studies.
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
Recruiting
The primary objective of the Outpatient Treatment with Anti-Coronavirus Immunoglobulin (OTAC) (INSIGHT 012) trial is to compare the safety and efficacy of a single infusion of anti-COVID-19 hyperimmune intravenous immunoglobulin (hIVIG) versus placebo among adults with recently diagnosed severe acute respiratory syndrome - coronavirus 2 (SARS-CoV2) infection who do not require hospitalization. The primary endpoint of this double-blind randomized trial is a five-category ordinal outcome that asse... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: COVID, SARS-CoV2 Infection, Covid19
Strategies and Treatments for Respiratory Infections & Viral Emergencies (STRIVE): Shionogi Protease Inhibitor (Ensitrelvir)
Recruiting
Treatments are needed to improve outcomes among patients hospitalized for COVID-19, including direct-acting antiviral (DAA) agents to mitigate the pathology driven by ongoing viral replication. This trial will evaluate S-217622 (ensitrelvir), an anti-SARS-CoV2 3C-like protease inhibitor (PI) developed by Shionogi &; Co. Ltd. The study design is a randomized, placebo-controlled, multi-center international clinical trial that will evaluate the clinical efficacy of ensitrelvir when given in additi... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/12/2024
Locations: Baylor, Scott and White Health (301-003), Dallas, Texas +2 locations
Conditions: COVID-19
Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation Strategy Trial
Recruiting
COVID-19 can trigger a dysregulated immune response, and previous studies have shown that immune modulation can improve outcomes in hospitalized patients. This trial is designed to determine whether intensification of immune modulation early in the course of the disease (while patients are on low flow oxygen) with abatacept (active arm) combined with standard of care (SOC) improves recovery as compared with placebo + SOC (placebo arm). For both groups, intensification of immunomodulation will be... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/03/2024
Locations: Parkland Health and Hospital Systems (084-002), Dallas, Texas +2 locations
Conditions: COVID-19
A Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid
Recruiting
Purpose: To decrease symptom burden, improve cognitive function, improve endurance, and decrease fatigue in subjects with post-acute sequelae of COVID-19 (PASC) or "long-hauler" COVID using amantadine. If amantadine use is determined to be efficacious in this population, the findings of this study will be used towards a subsequent randomized control trial.
Gender:
All
Ages:
Between 20 years and 65 years
Trial Updated:
05/30/2024
Locations: UT Southwestern Medical Center, Dallas, Texas
Conditions: Long COVID, Post-Acute COVID-19 Syndrome
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
Recruiting
The purpose of this clinical trial is to learn about the safety, extent of the side effects, and immune responses of the study vaccine (called variant-adapted BNT162b2 RNA-based vaccine) in healthy children. The trial is divided into 5 individual studies or substudies based on age group and prior history of COVID-19 vaccinations. All participants in each of the 5 sub-studies will receive study vaccine as a shot depending on what group they are in. Substudy A design: Phase 1 includes participant... Read More
Gender:
All
Ages:
Between 6 months and 11 years
Trial Updated:
05/13/2024
Locations: Cedar Health Research, Dallas, Texas
Conditions: SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19
Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
Recruiting
The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.
Gender:
All
Ages:
Between 0 years and 20 years
Trial Updated:
03/29/2024
Locations: University of Texas-Southwestern Medical Center Dallas, Dallas, Texas
Conditions: Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Hemophilia, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Antimicrobial Resistance During the SARS-CoV-2 (COVID-19) Pandemic
Recruiting
Assess the incidence and rates of resistant pathogens prior to and during the COVID-19 pandemic.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Methodist Dallas Medical Center, Dallas, Texas
Conditions: COVID-19
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
Recruiting
Adults who do not have major health, kidney, gastrointestinal disease will be randomized to receive oral mitoquinone/mitoquinol mesylate (Mito-MES) versus placebo to prevent the development and progression of COVID-19 after high-risk exposure to a person with confirmed SARS-CoV-2 infection.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/07/2024
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: SARS-CoV Infection, COVID-19
Methodist Health System COVID-19 Patient Registry
Recruiting
This is a prospective cohort observational registry study that will include data on all patients who are treated at MHS facilities for COVID-19.
Gender:
All
Ages:
18 years and above
Trial Updated:
07/06/2023
Locations: Clinical Research Institute Methodist Health System, Dallas, Texas
Conditions: COVID-19
Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults
Recruiting
A randomized, observer-blind, placebo-controlled immuno-bridging, and broadening study to demonstrate the equivalence of the immune response between participants enrolled in Phase 3 efficacy trial in India and demographically diverse healthy adult participants in the US which matched in age and vaccine formulation setting to whom those efficacy results are extrapolated; and to assess the broadening of the BBV152 in participants who previously received two shots of messenger ribonucleic acid (mRN... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/24/2023
Locations: PRX Research, Dallas, Texas
Conditions: COVID-19
Study to Evaluate the Efficacy and Safety of AstroStem-V in Treatment of COVID-19 Pneumonia
Recruiting
This study is an open-label, single-arm study to evaluate the safety and efficacy of Astrostem-V, allogenic adipose tissue derived mesenchymal stem cells (AdMSC), in patients with COVID-19 pneumonia. After each subject completes 12-Weeks visit (Visit 12) and the data management team confirms all individual data have no issue, the individual database will be locked and the blinding will be open for the statistical analysis.
Gender:
All
Ages:
Between 19 years and 80 years
Trial Updated:
01/09/2023
Locations: Epic Medical Research, Dallas, Texas
Conditions: Covid19 Pneumonia
Evaluation of the Clinical Impact of Corticosteroid Duration on SARS-CoV-2 (COVID-19 WHO)
Recruiting
The purpose of this project is to evaluate the clinical impact of the use of glucocorticoids beyond 10 days for patients with critical COVID-19 at MDMC.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/21/2022
Locations: Methodist Dallas Medical Center, Dallas, Texas
Conditions: Covid 19